Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Completes $20M Stock Offering

NEW YORK (GenomeWeb) – WaferGen Biosystems announced today that it has completed an offering of common stock and warrants that brought in gross proceeds of $20 million.

The offering comprises 2,000 units priced at $10,000 per unit. Each unit consists of 2,000 shares of common stock and 2,000 warrants to purchase shares of the firm's common stock. In total, 4 million shares of common stock and warrants to purchase 4 million shares were issued in the offering. The warrants have a term of five years and an exercise price of $5 per share.

The offering brought in net proceeds of approximately $18 million. WaferGen said that it intends to use $1.3 million of the funds to repay existing debt, and the rest will be used for general corporate and working capital purposes.

Ladenburg Thalmann & Co. was the sole book-running manager for the offering, while National Securities Corp. and Brean Capital were co-managers on the offering.

Last Friday, when the firm announced the offering, its shares dropped more than 50 percent to close at $4.95. In afternoon trading today, WaferGen shares were up a fraction of 1 percent at $4.60.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.